Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

Expanded MS franchise drives growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Idec

4Q Revenues: $2.0 billion (+39%)

4Q Earnings: $457.3 million (+57%)

FY Revenues: $6.9 billion (+26%)

FY Earnings: $1.9 billion (+35%)

Comments: Growth in the quarter and FY were driven by sales of new multiple sclerosis drug, Tecfidera, with sales of $398 million in the quarter and $876 million for the year, and TYSABRI revenues, up 45% to $427 million in the quarter, and up 34% for the year to $1.5 billion, as a result of recording 100% of revenues after gaining full rights. AVONEX revenues were flat in the quarter at $751 million and up 3% for the year to $3.0 billion. Royalty revenues were $61 million in the quarter, up 9%, and $186 million for the year, up 10%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters